Concepedia
Statistics
Publications
19
Citations
3.4K
H-Index
17
Active since
1993
Affiliations
Pfizer (United States)(Current)
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Peter MacCallum Cancer Centre
Institut Gustave Roussy
Leonard P. James is an author at Pfizer (United States) specializing in medicine, pharmacology, and oncology.
Publications per year
1993–2021
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations
Medicine, Oncology, Medical Oncology +10
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text
Medicine, Oncology, Pharmacology +14
Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F
Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 484 citations · Full text
Medicine, Oncology, Pharmacology +16
Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer
Binsheng Zhao, Leonard P. James, Chaya S. Moskowitz et al. · Radiology · 2009 · 342 citations · Full text
Medicine, Oncology, Radiology +13
Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC).
D. Ross Camidge, Sai‐Hong Ignatius Ou, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2014 · 256 citations
Medicine, Oncology, Pharmacology +13
1–5 of 19